Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.
Clinical trial NCT03168022 · COMPLETED
Trial details
- NCT number
- NCT03168022
- Sponsor
- Tonix Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-16
- Primary completion
- 2016-01-26
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.